title: CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
abstract: At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.
authors.affiliation: Department of Microbiology and Immunology, Mucosal Immunology and Vaccine Research Center, Institute of Biomedicine, University of Göteborg, Box 435, 40530 Göteborg, Sweden.
authors.forename: Dubravka Grdic
authors.initials: DG
authors.lastname: Eliasson
authors.forename: Karim
authors.initials: K
authors.lastname: El Bakkouri
authors.forename: Karin
authors.initials: K
authors.lastname: Schön
authors.forename: Anna
authors.initials: A
authors.lastname: Ramne
authors.forename: Els
authors.initials: E
authors.lastname: Festjens
authors.forename: Björn
authors.initials: B
authors.lastname: Löwenadler
authors.forename: Walter
authors.initials: W
authors.lastname: Fiers
authors.forename: Xavier
authors.initials: X
authors.lastname: Saelens
authors.forename: Nils
authors.initials: N
authors.lastname: Lycke
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal; D007114:Immunization; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics / Q000472:pathogenicity; D053122:Influenza A Virus, H3N2 Subtype / Q000235:genetics / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009976:Orthomyxoviridae Infections / Q000276:immunology* / Q000517:prevention & control; D016865:Reassortant Viruses / Q000235:genetics / Q000472:pathogenicity; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000086082:Viroporin Proteins
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D002772:Cholera Toxin; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007252:Influenza Vaccines; D011993:Recombinant Fusion Proteins; D014763:Viral Matrix Proteins; C440610:CTA1-DD protein, recombinant; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins; C509609:M2e-HBc influenza vaccine